Abstract
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Volume: 7 Issue: 3
Author(s): Wim J. Oyen, E. J. Postema, Frans H. Corstens, Otto C. Boerman and Manuel J. Koppe
Affiliation:
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Abstract: Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Export Options
About this article
Cite this article as:
Oyen J. Wim, Postema J. E., Corstens H. Frans, Boerman C. Otto and Koppe J. Manuel, Radionuclide Therapy of Cancer with Radiolabeled Antibodies, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618126
DOI https://dx.doi.org/10.2174/187152007780618126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
Mini-Reviews in Medicinal Chemistry Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting
Current Drug Targets Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy
Anti-Cancer Agents in Medicinal Chemistry Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Prospects of Embryonic Stem Cells in Treatment of Hematopoietic Disorders
Current Pharmaceutical Biotechnology Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers
Current Medicinal Chemistry Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets